Johnson & Johnson to acquire $2 billion drug developer "Ambrx Biopharma" to treat Turbo Cancers with same tech as Pfizer's $43 billion Seagen acquisition. Both set their sights on 2025 Cancer TSUNAMI
Keep reading with a 7-day free trial
Subscribe to COVID Intel - by Dr.William Makis to keep reading this post and get 7 days of free access to the full post archives.